Raphael Szalat MD, PhD

Assistant Professor, Hematology & Oncology

820 Harrison Ave | (617) 638-7011
Raphael Szalat

Biography

I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.

Education

Medicine, MD, Université Paris-Sorbonne, Paris IV, 2010

PhD, Université Paris-Sorbonne, Paris IV, 2019

Publications

Published on 10/10/2022

Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2022 Oct 10; JCO2200643. PMID: 36215675.

Published on 7/5/2022

Bertrand KA, Zirpoli G, Niharika Pillalamarri B, Szalat R, Palmer JR, Kataria Y. Prevalence of monoclonal gammopathy of undetermined significance in US black women. Am J Hematol. 2022 Sep; 97(9):E341-E343. PMID: 35723873.

Published on 7/5/2022

Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199. PMID: 35731907.

Published on 11/18/2021

Bazarbachi AH, Avet-Loiseau H, Szalat R, Samur AA, Hunter Z, Shammas M, Corre J, Fulciniti M, Anderson KC, Parmigiani G, Treon SP, Mohty M, Munshi NC, Samur MK. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985. PMID: 34792571.

Published on 11/15/2021

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab. Am J Hematol. 2022 01 01; 97(1):79-89. PMID: 34739735.

Published on 9/28/2021

Fillmore NR, Cirstea D, Munjuluri A, Yameen H, Yellapragada SV, Do NV, Brophy MT, Szalat RE, Munshi NC. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514. PMID: 34428278.

Published on 6/25/2021

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M. Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel). 2021 Jun 25; 13(13). PMID: 34202390.

Published on 6/1/2021

Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, Do NV, Brophy MT, Munshi NC. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698. PMID: 33031532.

Published on 4/29/2021

Hassan H, Szalat R. Genetic Predictors of Mortality in Patients with Multiple Myeloma. Appl Clin Genet. 2021; 14:241-254. PMID: 33953598.

Published on 2/2/2021

Acevedo J, Doros G, Szalat R, Sanchorawala V. Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. Clin Lymphoma Myeloma Leuk. 2021 06; 21(6):425-426. PMID: 33622658.

View full list of 47 publications.